Treating depression in dialysis patients: pharmacological and non-pharmacological approaches Authors: Daniel Cukor, Christian Cornelius, Kate Dahl, Daniela Figueiredo, Helena Sousa, Ava Archey, Paul L Kimmel Published: 2026 ABSTRACT ABSTRACTDepression is relatively common in patients with kidney failure treated with hemodialysis, and the prevalence rate exceeds that of the general population. Depression should be treated in people maintained on dialysis, both due to depression’s inherent significance and its potential complications of kidney treatment. This paper reviews the relevant literature on reported pharmacological and non-pharmacological approaches. Although the evidence base is somewhat limited, recent clinical trials have allowed the formulation of practical treatment recommendations. The literature on pediatric chronic kidney disease is also reviewed. Although the evidence base is scarce, treatment recommendations for the pediatric population are discussed. Various barriers to the integration of standardized depression screening and treatment for people with kidney failure treated with hemodialysis are reviewed. Since treatment of end-stage kidney disease (ESKD) became a reality, depression was variably thought to be a relatively minor problem, a simple consequence of patients reacting to the cataclysm of starting an arduous therapy that includes reliance on machines, disfiguring surgery, dependence on others, and shortened lifespans. Although some early researchers raised concerns about depression as a concomitant of ESKD [1–8], for the most part interest in the problem lagged behind. Given the large ESKD hemodialysis (HD) patient populations and in the absence of universal screening with consistent methods and measurements, it is difficult to precisely establish rates for the prevalence and incidence of depression in dialysis patients. Epidemiologic rates may vary across regions and countries, depending on whether self-screening schemes, clinical questionnaires, or diagnostic interviews are employed [9–11]. Over the last 50 years, numerous estimates of the prevalence of depression in this population have been reported, including mostly small studies [9, 10]. A comprehensive review of many small and large studies across the globe, using various ascertainment methods, provided a prevalence estimate of 22.8% [9]. While it was often stated, without evidence, that depression is the most common psychological complication in ESKD patients, recent studies in which many variables are measured reasonably suggest the prevalence of anxiety exceeds that of depression in these populations [8]. Depression, however, is quite significant due to its many known associations with potentially harmful psychological and medical factors in people with kidney failure (Fig. 1). Factors associated with increased depression in people with end-stage kidney disease. As study populations increased in size and became more diverse, with the use of large nationally or international registry databases (e.g. Medicare, the United States Renal Data System, and the European Renal Association), associations between increased depressive affect and a set of negative psychosocial variables, such as poorer perceptions of quality of life and decreased social support, as well as increased symptom burden were consistently identified [12–16] (Fig. 1). Perhaps the gravest association established between depression and outcomes were early links noting [17–20] and later studies assessing increased and sustained depressive affect and mortality in dialysis patients [21–23]. Such findings must be more extensively replicated in pediatric ESKD populations, through the use of multicenter studies, administrative databases, and randomized controlled trials. Finally, in the 21st century, randomized controlled studies provided evidence that pharmacologic treatments of depression, established in general populations, are safe and effective in ESKD patients maintained on dialysis, and that non-pharmacologic approaches, such as cognitive behavioral therapies are equally useful [24, 25]. Treatment studies in ESKD HD patients have also shown that effective interventions targeting depression can improve related negative psychosocial variables [26, 27]. Because of the paucity of randomized controlled trials in ESKD populations, many recommendations must be based on studies in more general populations. DEPRESSION TREATMENT IN THE GENERAL POPULATION As depression can stem from a confluence of biopsychosocial sources, a multidisciplinary treatment approach may be needed to provide symptom relief. Recommendations for the initial treatment of adults living with depression highlight the value of shared decision-making between provider and patient [28–30]. The American Psychological Association (APA) published an umbrella review on the treatment of depressive disorders and clinical guidelines [31]. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), or psychotherapy were endorsed as first line treatments. If combined pharmacologic and psychological intervention is initiated, they recommended cognitive and behavioral therapies or interpersonal psychotherapy, with an SSRI [31]. The American College of Physicians published treatment guidelines for episodic Major Depression [32]. Similar to the APA’s guidelines, they recommended either pharmacologic or non-pharmacologic monotherapy as initial treatment, endorsed SSRIs and SNRIs as the best initial pharmacologic option, but identified only Cogitive Behavioral Therapy (CBT) as the non-pharmacologic monotherapy of choice, compared to other psychotherapies, complementary and alternative medicine strategies, or exercise [32]. Pharmacologic intervention options for depression in the general population have increased, and choosing a medication includes evaluating in a patient’s clinical symptoms, medical comorbidities, potential drug interactions, and previous responses to medications [32]. The different antidepressant classes include: SSRIs (sertraline, fluoxetine, citalopram, escitalopram, fluvoxamine, paroxetine), SNRIs (venlafaxine, desvenlafaxine, duloxetine, levomilnacipran), tricyclic antidepressants (TCAs) (amitriptyline, nortriptyline, imipramine, desipramine, doxepin), monoamine oxidase inhibitors (MAOIs) (phenelzine, tranylcypromine, selegiline, moclobemide, isocarboxazid), the norepinephrine dopamine reuptake inhibitor bupropion, the selective noradrenaline reuptake inhibitor reboxetine, the noradrenergic serotonin antagonist and reuptake inhibitor trazodone, the specific serotonergic antidepressant mirtazapine, serotonin modulators (vilazodone, vortioxetine), the specific serotonin melatonin antidepressant agomelatine, and NMDA receptor antagonists (ketamine, esketamine, dextromethorphan/bupropion). Selection of a specific antidepressant medication might focus on minimizing specific side effect profiles, such as having less sedation, minimizing weight gain, reducing cardiovascular risks, or having less sexual dysfunction [33]. Alternatively, certain antidepressants may be more advantageous in certain clinical situations, such as addressing insomnia, chronic pain treatment, or fatigue reduction [33]. Regardless of which medication is chosen, about 40% of patients do not respond to the initial treatment and about 70% do not reach remission of symptoms in more general populations [34]. Starting doses of antidepressants are typically lower than the targeted doses to which patients tend to ultimately respond, and partial responses can often be remedied by increasing the dosage at 2–4 weeks as tolerated [33]. Augmentation strategies are often recommended in cases of partial response after adequate time and dose of an antidepressant are given. However, it is likely more valuable to change antidepressant classes rather than augment if no response was gained after an adequate antidepressant trial [33]. The treatment of depression using non-pharmacological approaches spans a wide gamut of interventions [31], including supplements [35], activity interventions [36], interventional psychiatry [37], and psychotherapy [38]. While several forms of psychotherapy have received clinical attention, CBT emerges as the most studied effective non-pharmacological treatment for depression in the general population [39–42]. CBT is based on the early observation that people who were depressed tended to have the perception that negative events were due to internal (as opposed to external) factors, were stable (as opposed to transient) and global (as opposed to due to a specific circumstance) [43]. CBT strategies include identifying the relationships between one’s thoughts, feelings and actions, and then evaluating the utility of those perceptions [44]. CBT has been shown to be effective at improving a variety of behavioral health concerns [45–48], reducing depression in diverse patient populations [49–52], and can be delivered through various treatment modalities [53–55]. PHARMACOLOGIC INTERVENTIONS IN HEMODIALYSIS PATIENTS WITH DEPRESSION Despite the high prevalence of depression in patients treated with dialysis, most do not receive treatment [24, 56–58]. Zhang et al. conducted a randomized controlled trial of 125 HD patients with depression, half treated with sertraline and found the treatment group had reduced depression, improved quality of life, improved adherence with HD, and the sertraline group had lower chronic inflammation, less malnutrition, and less anemia [59]. Depression is associated with an increased risk of progression to ESKD, hospitalization, and death [60]. Addressing depression is important given the high rate of suicide or hemodialysis withdrawal in hemodialysis patients (50 times that in the general population), which is especially high within the first 3 months of starting dialysis [61–63]. The use of antidepressant medications in patients treated with HD is not without associated risks. Ishida et al. reported older HD patients treated with antidepressants had increased risks of altered mental status, falls, and fractures [64]. Antidepressant medications can increase the risk of gastrointestinal bleeding due to anti-platelet effects by 55%, with the risk increasing by 2.5 times if combined with other antiplatelet medications in general populations. Adding acid suppressing medications can reduce the risk of gastrointestinal bleeding when SSRIs and antiplatelet medications are used in combination [65]. Antidepressants can cause QTc prolongation to varying degrees in HD patients already at increased risk of arrhythmia due to comorbidities and electrolyte disorders [66]. Therefore, the selection of a particular antidepressant medication must take into account medical comorbidities, drug–drug interactions, and QTc monitoring, along with educating patients regarding the risks and benefits, using shared medical decision-making. NON-PHARMACOLOGIC INTERVENTIONS IN HEMODIALYSIS PATIENTS WITH DEPRESSION Recent reviews of non-pharmacological treatments of depression in people with ESKD [67–74] concluded that based on the limited trial data available, only CBT shows indication of effectiveness for the treatment of depression. The majority of studies considered were small scale trials with methodological challenges [67, 71]. While exercise as a non-pharmacological intervention has received significant clinical interest, it has had limited testing in depressed ESKD populations [75–79]. The ability to demonstrate mood improvement in non-depressed population is not equivalent to a depression intervention in depressed sub-populations [75]. In general populations, CBT is the most studied and endorsed non-pharmacological intervention for depressed individuals [80]. Recent clinical trials with improved methodologies have extended these findings to people with ESKD. The ASCEND trial [24] compared CBT delivered during dialysis, chair-side, to algorithmic-based sertraline prescription in 120 in-center HD patients in three US cities. Patients randomized to the psychotherapeutic intervention received 10 CBT sessions with a therapist, over 12 weeks. The CBT was modified for the particular needs of people with ESKD and was selected based on its previously demonstrated effectiveness [81]. The study found about the same level of effectiveness for both treatment strategies, with a slight statistical advantage for the sertraline arm, which had substantially more adverse events [24]. The authors concluded that both treatments appeared to be effective. In post-hoc analyses of the interventions, it was suggested that high rates of comorbid anxiety differentially complicated the CBT treatment [82]. The “Improving Distress in Dialysis” study [83] tested an online CBT intervention customized for HD patients reporting at least some elevation in depression symptoms. The study had poor engagement, largely due to low computer literacy (53%) and a low rate of acceptability (44%). Over 40% of the population declined to participate due to perceived lack of need for the intervention [83]. While technology supported CBT may seem like an attractive treatment option to providers, many patients did not engage. Furthermore, targeting patients with clinically elevated levels of depression seems to be required for patient engagement and buy-in. Another recent study, the TACcare trial, randomized 160 HD participants with ESKD to a stepped care approach to address the symptoms of pain, insomnia, and depression or control condition [84]. The intervention group received a “stepped” approach to pharmacotherapy and/or CBT. The Control Group received only weekly health education sessions. The study found clinically and statistically significant reduction in fatigue and pain, and small improvement in depression in the intervention group compared to the control condition. Depression reduction was modest (-1.73 on the BDI-II) (the minimally clinically significant change is considered five points) [85], but participants in this trial did not necessarily meet criteria for depression, as having an elevation in any of the symptoms targeted was grounds for inclusion. Interestingly, the majority of patients in the intervention group preferred CBT over adding new medications, highlighting a strong patient preference for non-pharmacological symptom management. The HOPE Consortium Trial [25] tested the ability of Pain Coping Skills Training (PCST), an adapted form of CBT [86], to reduce pain interference more than standard care. The trial recruited a national U.S. sample of 640 adult patients treated with maintenance HD who reported chronic pain. The study found that the PCST intervention significantly reduced pain interference (the study’s primary outcome) more than the usual care group. The PCST group also showed improvements in depression and anxiety. While these changes were statistically significant, similar to the TACcare trial, they were of a small magnitude, likely due to the lack of elevated depression scores as a study inclusion criterion. CLINICAL TREATMENT OF DEPRESSION The approach to treatment of depression in patients with dialysis-dependent ESKD differs from the typical treatment of depression in the general population, and data supporting treatment in this population is limited (see Fig. 2 and Table 1). Suggested treatment algorithm for depression in people treated with HD. Please note that recommendations are largely based on expert opinion and are often made in the absence of randomized controlled trials specifically designed to test hypotheses regarding therapy in well-defined populations. Table 1:Antidepressant treatment in HD.AntidepressantStarting doseMaximum dosingClinical pearlsSertraline25 mg50–200 mg, no reductionOften first choiceFluoxetine10 mg20–60 mg range, reduce maxLong half-life Paroxetine Limited trials using low doses 2D6 drug interactions Fluvoxamine Limited trials using low doses 1A2 drug interactions Escitalopram Alternatives suggested QT prolongation high risk Citalopram Avoid QT prolongation highest risk Venlafaxine37.5 mg112.5 mg q dayTaper slow; dose after dialysis; limited dataDesvenlafaxine25 mg q 48 h25 mg q dayTaper slow; dose after dialysisMirtazapine7.5 mg15–22.5 mgLess GI bleed; mortality riskBupropion150 mg q 72 h150 mg q dayToxic metabolite accumulation Duloxetine Avoid Substantial toxic metabolite accumulation Antidepressant treatment in HD. CONSIDERATIONS REGARDING PHARMACOLOGIC TREATMENTS Patients treated with HD who screened positive for depression have shown a lack of interest in starting or modifying depression treatment [87]. Effective antidepressant responses can be delayed in chronic kidney disease (CKD) patients. Instead of expecting a full response within 4–6 weeks, up to 12 weeks of treatment may be needed [88]. It is prudent to initiate antidepressant medications at reduced starting doses, and sometimes reduced maximum doses, as decreased kidney function affects medication pharmacokinetics by changes in absorption, volume of distribution, protein binding, fat solubility, and reduced P450 enzyme metabolism [89, 90]. The higher prevalence of mild adverse effects of medications in this population may be explained by the prolonged elimination half-life and reduced clearance of many antidepressant medications in patients with reduced renal function [91]. Fortunately, most psychotropic medications are large, fat-soluble molecules that have high protein binding and are not significantly affected by dialysis [89]. If less than 30% of a medication is renally cleared, adjustments are not needed after dialysis [92]. The European Renal Best Practice statement from 2014 recommended the use of SSRIs for 8–12 weeks in dialysis patients with moderate/major depression, followed by treatment re-assessment after 12 weeks [93]. Sertraline requires no dose adjustments apart from low initial doses and has a more favorable profile with fewer drug interactions. Sertraline is also useful in reducing intra-dialysis hypotension and treating uremic pruritis [94, 95]. While sertraline, citalopram, and escitalopram share lower rates of drug interactions, sertraline is preferrable given recent evidence for response in this population and safety profile with sertraline having lower QTc prolongation risks. Assimon et al. compared QTc-prolonging SSRIs with higher risk (citalopram, escitalopram n = 30 932) and lower risk (fluoxetine, fluvoxamine, paroxetine, sertraline n = 34 722) drugs. They found starting a higher QT-prolonging SSRI was associated with a 1-year increased risk of sudden cardiac death in HD patients (adjusted hazard ratio 1.18) [96]. This association was more pronounced in patients over 65 years, female, persons with a cardiac conduction disorder and those using additional non-SSRI QT-prolonging medication [96]. Citalopram has a higher risk of QT prolongation than escitalopram and generally should be avoided in HD patients who are already at increased risk of arrhythmia. Since there are alternative antidepressants with less QT prolonging risk, some authors also recommend avoiding escitalopram in HD patients as well [97]. It is important to note that escitalopram and citalopram increase QT prolongation in a dose-dependent fashion [98]. Other SSRIs include fluoxetine (2D6 inhibitor), fluvoxamine (1A2 inhibitor), and paroxetine (2D6 inhibitor), and should be appropriately considered before prescribed to HD patients. The prescriber should check for any potential drug interactions in patients treated with multiple medications, to lessen the risk of adverse drug reactions. Fluoxetine’s long half-life has potential advantages in patients who have inconsistent adherence with medications, by lessening the risk of antidepressant withdrawal to occasionally missed doses. Kauffman et al. studied this further, using a once weekly formulation of fluoxetine in 16 HD patients who were transitioned from 20 mg daily oral fluoxetine after 2 weeks to a once weekly formulation at doses of 90–180 mg given at dialysis. At 12 weeks, 14 of 16 patients no longer met criteria for major depression [99]. The typical dose range of fluoxetine is 20–60 mg but due to the long half-life and potential for accumulation reducing the maximum dose is recommended. Paroxetine is not an ideal first-line therapy, due to 2D6 drug interactions. Paroxetine requires dose reduction due to increased blood levels in renal disease, with levels twice normal with GFR 30–60 and 3.5 times normal with GFR < 30 [88]. Fluvoxamine is a strong CYP1A2 inhibitor that can interact with some medications, with about 22% dialyzed [100]. Both paroxetine and fluvoxamine lack controlled studies in HD patients compared to other SSRIs, with only limited observational trials being reported using low doses [101]. If SSRIs are either ineffective or not tolerated, trying another class of antidepressant is an option, recognizing that the clinical evidence to guide therapy in this population are quite limited. Both venlafaxine and desvenlafaxine levels are significantly affected in kidney failure (up to 50%). Each drug requires a dose reduction not to exceed 50% of maximum doses [102]. There are no controlled trials using these agents for depression in HD patients, but dose restrictions suggest a maximum of 112.5 mg for venlafaxine and 25 mg for desvenlafaxine in HD patients [88]. Mirtazapine also has the potential for accumulation in patients with kidney failure, with a 50% reduction in clearance and 215% increase in area under the curve in 10 patients, 7 of whom were treated with HD. Mirtazapine dosing should be reduced by 50% in severe renal disease, and HD studies were done using the 15 mg dose only [103, 104]. Mirtazapine serum levels decrease significantly (28%) after dialysis [93]. Mirtazapine has been suggested as a “one-drug intervention” in ESKD patients, because it targets itching, insomnia, nausea, loss of appetite, depression, and anxiety [105]. While no depression trials exist for mirtazapine in HD patients, two studies (N = 55, N = 77) using mirtazapine (15 mg) to treat pruritis in HD patients found it to be effective and associated with improved sleep [106, 107]. A 2024 study of nearly 8000 non-HD CKD patients found that initiating antidepressants was not associated with long-term outcomes of all-cause mortality, major cardiovascular events, or CKD progression. In comparison with SSRIs, mirtazapine was associated with a lower risk of upper GI bleeding (HR 0.52) but a higher mortality risk in patients with chronic kidney disease (HR 1.11) [108]. Duloxetine is not recommended in patients with severe renal failure (GFR < 30 ml/min) per the manufacturer and the Food and Drug Administration (FDA), as drug levels increase multifold, and there is an up to nine-fold accumulation of toxic metabolites [109]. While outside the United States, European guidance allows for possible use of duloxetine at lower doses in patients with ESKD [110], only low doses (no higher than 40 mg/day) should be used, as clearance further declines with higher doses. Close monitoring for side effects (headaches, nausea, somnolence) or signs of toxicity (hypertension, myoclonus, tachycardia, seizure) is warranted [104, 110]. Bupropion is primarily hepatically metabolized to the active metabolite hydroxybupropion, which is not dialyzable and can become toxic in patients with decreased kidney function, possibly related to downregulation of the P450 enzyme 2B6 in those with renal disease [111]. Based on HD studies using bupropion for smoking cessation, it is recommended to initiate treatment at 100 mg every 48 h or 150 mg every 72 h and titrate to a maximum of 150 mg per day [112]. The combination of bupropion with SNRIs (venlafaxine, desvenlafaxine, duloxetine) should be avoided due to significant drug interactions leading to SNRI toxicity [113]. TCAs historically have been used in patients with ESKD for chronic pain, insomnia, and depression. However, they would not be a preferred choice as a class in treating depression in HD patients, given anticholinergic side effects, orthostatic hypotension, and QTc prolongation risk. Trazodone is prescribed more for insomnia than depression. Its effectiveness for depression was no better than placebo or CBT-I in HD patients and was more likely to be associated with serious adverse events, particularly cardiovascular events [114]. Milnacipran is not recommended in ESKD patients [115]. Limited data on reboxetine suggest reduced doses in HD patients [88]. Vilazodone and vortioxetine do not have recommended dose reductions in patients with renal disease, but studies are lacking in HD patients [116]. MAOI (selegiline, isocarboxazid, phenelzine) are either contraindicated in patients with kidney failure or lack data reported in patients with renal disease (moclobemide, tranylcypromine). CONSIDERATIONS REGARDING NON-PHARMACOLOGIC TREATMENTS Cognitive behavioral therapy for depression has been shown to be effective in people with comorbid depression and medical illnesses [117–120]. CBT appears to be more effective, given certain patient, provider and presentation factors. Patients with a recent onset of psychiatric symptoms, lower symptom severity, and fewer comorbidities tend to have a more positive treatment response [121–123]. Similarly, patients with better cognition, higher self-efficacy, and positive attitudes about treatment all seem to benefit more from CBT [124–126]. Therapists who are more experienced with CBT in general and with the particular presenting problem tend to also provide better outcomes [125]. Models combine CBT treatment for psychological adjustment to long-term physical health conditions and illness self-management behaviors, as often the psychological and medical presentations are intertwined [127]. Furthermore, adaptation of CBT intervention to the unique needs of the specific medical population served may add to its efficacy [128]. There is a limited literature on adapting CBT for people with CKD or ESKD, but modifications to both the content and delivery of CBT when offered to people with advanced CKD or ESKD may be needed [129]. CBT treatment of depression can be expanded to include other commonly occurring mental and behavioral health symptoms [130]. In particular, the treatment for depression can be expanded to include modules on motivation, adherence, sleep, anxiety, and pain [26]. It has been posited that since anxiety and depression so often co-occur, an overt focus on anxiety should be incorporated into standard depression care for people with ESKD treated with HD [82]. There may be particular challenges in the ability of people with CKD to follow through on specific recommendations often made in treatment. The demands of dialysis treatment, for example, may prevent people from making the necessary adjustments to their sleep schedules [131]. Beyond content modifications, the HD unit presents both opportunities and challenges in the delivery of psychotherapeutic interventions. While HD schedules provide a high likelihood that a particular patient will be present at a specific time, chairside treatment also has potential drawbacks, such as patient fatigue, challenges to privacy, and possible interference with the hemodialysis procedure [132]. More recent clinical trials have focused on remote delivery of live CBT [25, 83, 84, 114]. There is interest in, but limited encouraging data on adapting CBT for self-directed use online [78, 83, 133–137]. PEDIATRIC CONSIDERATIONS As with adults, depression represents a substantial burden for children and adolescents treated with dialysis. While there are limited data and few large-scale studies on depression in pediatric dialysis patients, those available suggest that prevalence falls between 10% and 66% [138–141]. Studies have highlighted female gender, accelerated progression of CKD, and onset of CKD before the age of 5 as risk factors for depression in pediatric CKD patients [138, 142]. The maxim “children are not small adults” applies as readily to their emotional, cognitive, and social development as it does to their biological development. Depression in children and adolescents often presents differently than in adults, in that it may be marked by irritability (versus depressed mood), and failure to gain weight (versus weight loss) [141]. Younger children lack the cognitive ability to articulate their feelings and, in turn, are more likely to exhibit increased irritability, behavioral changes, poor concentration, or unexplained physical complaints [143]. Vegetative symptoms such as poor energy, appetite and weight changes, and insomnia are more common in teenagers than in adults. For adolescents, social withdrawal associated with depression may occur within family relationships, though not with peers [144]. The incidence of depressive disorders increases significantly after puberty, particularly for girls [145]. Adolescence is also a time when children with CKD may experience accelerated progression to ESKD and the need for renal replacement therapy [146, 147]. Important social and emotional developmental milestones are interrupted or delayed as pediatric patients miss school and social activities, and make lifestyle adjustments due to the burdens of dialysis treatments. Adolescent patients may also struggle with the impact of dialysis on self-image, such as short stature due to growth restriction, scars after surgical procedures, medication side effects, and the presence of medical devices [142, 148]. There is limited research on effective interventions for depression in children and adolescents treated with dialysis. In the general pediatric chronic illness literature, CBT has emerged as the most well-supported intervention [149, 150]. The content and delivery of CBT is often adapted when working with children and adolescents with chronic illness. In general, younger children benefit from concrete, play-based techniques and visual tools that translate cognitive concepts into more easily accessible formats (e.g. coping stories, thought bubbles, and visual scales). Caregivers play an important role in coaching younger children as they develop emotion regulation strategies [151]. Adaptations for adolescents often include psychoeducation around physical illness and depression, restructuring of illness-related thoughts, stress management, relationship building, health-related skill building, and behavioral activation that accommodates illness-related barriers [152]. Given the integral role of the family system in the lives of children and adolescents, family involvement and family-based interventions may prove to be essential to successful treatment of pediatric patients with depression. Having a child treated with dialysis affects family routines, parental burdens and stress, and sibling dynamics [153]. Furthermore, parental psychopathology may impact a child’s engagement in therapeutic interventions and modulate treatment outcomes, highlighting the critical importance of appropriate referrals for caregiver mental health services [143]. Family-focused CBT and problem-solving therapy assist families in working collaboratively on challenges such as medication scheduling, school absences, or hospitalizations. Enhanced family cohesion and reduced conflict have been linked to both improved mood and better illness management in other chronic illness populations [154, 155]. To date, there have been no studies examining the use of SSRIs in children and adolescents treated with dialysis. In the United States, the FDA has approved two types of SSRIs to treat major depressive disorder (fluoxetine for children ages 8 years or older and escitalopram for adolescents ages 12–17 years), though these medications carry warnings about possible increased risk of suicidal thinking and behavior [156, 157]. A recent paper from the CKD in Children cohort study reported that ∼7% of the cohort had been prescribed antidepressants. The authors hypothesized that, due to limited data on the pharmacokinetics of these agents in pediatric populations, clinicians may exhibit greater caution in prescribing them and may preferentially recommend psychotherapy [158]. IMPLEMENTATION CHALLENGES IN REAL-WORLD SETTINGS Implementing evidence-informed depression treatment in hemodialysis patients requires navigating different systemic, workforce, contextual, and patient-level challenges that currently contribute to a substantial gap between clinical need and service delivery. System-level fragmentation and financial constraints Healthcare provision for HD patients typically operates with limited integration between nephrology and mental health services [159–161]. The absence of structured referral pathways and care coordination mechanisms leads to underdiagnosis and inconsistent depression screening, irregular referrals, and inadequate follow-up of identified cases [11, 161]. Furthermore, current bundled payment models for hemodialysis do not cover consultations with psychologists or psychiatrists, thereby disincentivizing dialysis centers from integrating these professionals into renal interdisciplinary teams [162]. Although non-pharmacological interventions for depression have been successfully implemented and shown positive results, most dialysis centers do not have mental health professionals on staff who are tasked with treating depression, relying only on project-based or research grant funding [26, 69, 163–166]. Lack of dedicated mental health funding limits the sustainability of integrating these services into routine kidney care. Workforce capacity and training in psycho-nephrology The workforce available for treating depression in HD patients faces significant capacity constraints and training gaps. Renal social workers, the primary providers of psychosocial support in the US, Canada, and the UK, face unsustainable caseloads and devote most of their time to administrative tasks, leaving minimal capacity for clinical interventions [166–169]. Beyond availability, dialysis staff frequently report lacking the skills and confidence to identify patients’ psychological struggles and being uncertain about appropriate assessment methods, treatment pathways, and referral procedures [168, 170, 171]. The medical complexity of kidney failure compounds these challenges. Symptom overlap between depression and uremic manifestations, such as fatigue, cognitive impairment, and sleep disturbances, raises diagnostic uncertainty, requiring specialized and continuous recognition of psychological symptoms, as well as coordinated medical–psychological assessment and management [172]. The shortage of psychologists and psychiatrists with training in psycho-nephrology limits the provision of evidence-informed care capable of effectively meeting the multifaceted needs of people treated with hemodialysis [11, 26, 165, 168]. The unique nature of hemodialysis treatment The HD setting presents distinctive implementation challenges for depression treatment. The dialysis attendance regimen—three sessions per week, each lasting approximately 4 h—creates opportunities for regular patient–provider interactions, but also imposes a substantial treatment burden [11, 173]. The typical physical infrastructure of dialysis centers, designed primarily for medical procedures, limits mental health care delivery due to open, noisy treatment floors that offer minimal privacy and discourage sensitive conversations [26]. Private rooms are rarely available, and chairside interventions during dialysis sessions are often hindered by patient fatigue and intradialytic complications like muscle cramps and/or hypotension [26, 174]. Off-site interventions may offer an alternative, but they also present additional logistical challenges, including travel costs and competing appointments, which may increase patient reluctance to take on another dialysis-related activity within an already demanding treatment regimen [68, 175]. Patient-level barriers Cognitive impairment and dementia are prevalent in HD populations, which, combined with multimorbidities, greatly decrease patients’ ability to participate in interventions requiring ongoing cognitive effort [176, 177]. The financial burden from medical expenses, diminished work capacity, and social isolation due to a demanding treatment schedule may further reduce patient motivation and availability for depression treatment [70, 175, 178, 179]. These challenges are amplified for racial and ethnic minorities, who are disproportionately affected by kidney failure and may face language discordance with dialysis providers, with a concomitant scarcity of culturally adapted psychological interventions [180–182]. Mental health stigma and low health literacy—both frequent in dialysis settings—may also lead to the normalization of psychological distress as an inevitable consequence of chronic disease, hindering the recognition of depression as a distinct, treatable condition [24, 178, 183]. In addition, limited digital literacy among many dialysis patients may restrict participation in technology-based interventions, which are increasingly being used as potential alternatives for providing psychological support for those with kidney failure [184–187]. Recommendations Emerging evidence suggests that strengthening depression treatment in hemodialysis settings requires coordinated system-level reforms, advocating for funding that integrates psychosocial care, workforce training, and the development of flexible patient-centered interventions. CONCLUSIONS Depression is relatively common in patients with ESKD treated with HD, and the prevalence rate exceeds that in the general population. Depression should be treated in dialysis patients, although multi-level barriers can complicate access and treatment. The high degree of associations of depression with mortality and other biopsychosocial factors in patients with ESKD, make it imperative that screenings, evaluations, and treatment of depression be undertaken [27, 28]. Limited evidence regarding specific medication therapies in patients with ESKD treated with HD with depression may constrain the strength of individual recommendations. This is especially true of pediatric and adolescent ESKD populations. The clinical problem, however, is prevalent, related to safety and other outcomes, and must be addressed by clinicians caring for patients, even in the absence of definitive data. Pharmacologic therapy for dialysis-dependent ESKD patients should be prescribed with care, as abnormal drug metabolism, drug–drug interactions, and adverse side effects can affect the safety and effectiveness of specific medications. Each anti-depressant medication has its own unique characteristics, which must be considered in individual cases. Non-pharmacologic therapies, such as CBT, hold the promise of effective treatment without adverse drug effects, but barriers pose challenges to widespread access. Systemic barriers to identification of cases, screening, access to psychiatric care and treatment of depression in patients with kidney failure exist and must be addressed by all clinicians caring for ESKD patients.